Treatment for mitochondrial diseases.

Area of Science:

• Genetics and Molecular Biology
• Neurology
• Metabolic Disorders

Background:

• Mitochondrial diseases stem from DNA mutations, causing widespread organ dysfunction.
• Current therapies offer limited support, and disease progression is often unchecked.
• Previous reviews overlooked trial biases, necessitating a critical re-evaluation of interventions.

Purpose of the Study:

• To identify and assess the quality of recent studies on mitochondrial disease interventions.
• To evaluate potential biases in existing clinical trials for these disorders.
• To highlight promising therapeutic strategies for future research.

Main Methods:

• Systematic review and bias assessment of published and unpublished studies.
• Application of revised Cochrane Collaboration guidelines for quality appraisal.
• Focus on interventions for mitochondrial and nuclear DNA-related disorders.

Main Results:

• Eight out of ten reviewed studies (seven published, three unpublished) indicated positive outcomes.
• Two interventions demonstrated efficacy in rigorously designed studies, warranting larger trials.
• Allotopic expression of the ND4 subunit showed promise for Leber hereditary optic neuropathy.

Conclusions:

• Several interventions show potential for treating mitochondrial diseases, but require further validation.
• Rigorous study design is crucial for evaluating therapeutic efficacy.
• Targeted gene therapy approaches, like ND4 subunit expression, represent a novel treatment avenue.